An overview of the current landscape of available treatment options for Demodex blepharitis is analyzed. This is a video synopsis/summary of a discussion involving Elizabeth Yeu, MD. Yeu discusses how ...

Eric D. Donnenfeld, MD; underscores the significance of an FDA approved treatment for Demodex blepharitis as well as past alternative treatments. This is a video synopsis/summary of an Insights ...

Credit: Tarsus Pharmaceuticals. Xdemvy is supplied as an ophthalmic solution containing lotilaner 0.25% (2.5mg/mL) in a 10mL bottle; it is expected to be available by the end of August 2023. The Food ...

XDEMVY is the first and only approved therapeutic for Demodex blepharitis, a highly prevalent eyelid disease that impacts approximately 25 million eye care patients in the U.S. XDEMVY targets the root ...

Please provide your email address to receive an email when new articles are posted on . Demodex blepharitis is so common that it makes up more than two thirds of all blepharitis cases. In fact, nearly ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Tarsus Pharmaceuticals has announced positive topline ...

IRVINE, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven ...

IRVINE, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize ...